Many studies have shown that GLP-1RAs can treat certain CVDs, such as atherosclerosis and hypertension, and the suggested mechanism involves more than blood glucose control (111, 112)
In the 64-week OASIS 4 trial (307 adults), mean weight loss was 13.6% under the treatment-policy analysis and 16.6% among participants who stayed on treatment, versus about 2% on placebo
Reference: Willard FS et al
These topics are expected to surface during the live provider visit rather than in the intake itself
Mochi Health does not bill insurance for compounded products, but it offers prior authorization assistance for branded GLP-1s if a patients plan covers them
If experiencing severe side effects or symptoms related to GLP-1 drug use, its important to seek medical attention immediately